Novartis Pursuing Generic Biologics; Says Brand And Generic Lines Co-Exist
Executive Summary
Novartis is positioning itself at the forefront of companies seeking approval of generic biologics with a pending application for human growth hormone
You may also be interested in...
Sandoz Gets New Leader: Is Restructuring Next For Novartis’ Generics Unit?
Novartis is focusing on operational efficiencies in its Sandoz generics business to address a difficult pricing environment in the U.S
Sandoz Gets New Leader: Is Restructuring Next For Novartis’ Generics Unit?
Novartis is focusing on operational efficiencies in its Sandoz generics business to address a difficult pricing environment in the U.S
Sandoz Omnitrope NDA Is Test For Follow-On Biologics; Pfizer Says No
Sandoz' pending NDA for Omnitrope appears ripe for an FDA decision